Last 205.00 GBp
Change Today +5.75 / 2.89%
Volume 8.2K
SLN On Other Exchanges
Symbol
Exchange
London
OTC US
As of 11:35 AM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Tim Freeborn B.A., A.C.A.

Finance Director, Company Secretary and Director, Silence Therapeutics plc
AgeTotal Calculated CompensationThis person is connected to 11 board members in 1 different organizations across 3 different industries.

See Board Relationships
55122,000 GBP
As of Fiscal Year 2013

Background*

Mr. Timothy Freeborn, also known as Tim, B.A., A.C.A, serves as a Company Secretary of Silence Therapeutics Plc and has been its Finance Director since October 2012. Mr. Freeborn served as the Head of Research at XCAP Securities plc, Research Division. He served as Equity Analyst at Evolution Securities Ltd., Research Division. Mr. Freeborn serves as a Director of Silence Therapeutics Plc.

Corporate Headquarters*

1 Lyric Square
London, Greater London W6 0NB

United Kingdom

Phone: 44 20 3700 9711
Fax: --

Board Members Memberships*

Finance Director, Company Secretary and Director

Education*

There is no Education data available.

Other Affiliations*

Annual Compensation*

Salary99,000 GBP
Bonus20,000 GBP
Total Annual Compensation119,000 GBP

Stock Options*

All Other Compensation3,000 GBP
Total Value of Options476,200 GBP
Total Number of Options310,000

Total Compensation*

Total Annual Cash Compensation122,000 GBP
Total Short Term Compensation119,000 GBP
Other Long Term Compensation3,000 GBP
Total Calculated Compensation122,000 GBP
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SLN:LN 205.00 GBp +5.75

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
J. Michael French Chairman, Chief Executive Officer, President and Principal Financial Officer
Marina Biotech, Inc.
$127.5K
Peter French B.Sc, M.Sc, Ph.D., MBAManaging Director, Chief Executive Officer and Director
Benitec Biopharma Limited
A$450.0K
Hans G. C. P. Schikan Chief Executive Officer and Member of Management Board
Prosensa Holding N.V.
--
Mark W. Schwartz Ph.D.Chief Executive Officer and President
Galena Biopharma, Inc.
$490.0K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SILENCE THERAPEUTICS PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.